Evolus, Inc. (NASDAQ:EOLS) Receives $16.00 Consensus PT from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.00.

EOLS has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a report on Wednesday, June 17th. Wall Street Zen cut Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th.

Evolus Stock Performance

Shares of EOLS stock opened at $6.85 on Friday. The stock’s fifty day moving average is $6.56 and its two-hundred day moving average is $5.54. The firm has a market capitalization of $451.14 million, a P/E ratio of -10.22 and a beta of 1.32. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $10.20.

Evolus (NASDAQ:EOLS) last released its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. During the same period last year, the firm earned ($0.30) earnings per share. On average, equities analysts forecast that Evolus will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC grew its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the period. Meeder Asset Management Inc. purchased a new position in Evolus during the fourth quarter worth about $34,000. Wexford Capital LP purchased a new position in Evolus during the third quarter worth about $37,000. Tower Research Capital LLC TRC boosted its holdings in Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after purchasing an additional 5,691 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in Evolus in the 3rd quarter valued at about $48,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.